

10

15

20

25

30

35

8. The method of claim 3, wherein said TNF binding protein and said *fas* fusion protein are administered in a pharmaceutically acceptable carrier.

9. A pharmaceutical composition comprising a TNF binding protein and an additional anti-inflammatory drug.

5

10. The pharmaceutical composition wherein the anti-inflammatory drug is methotrexate.

10 11. The pharmaceutical composition wherein the anti-inflammatory drug is a fas fusion protein.

15 12. The pharmaceutical composition of claim 9, wherein said TNF binding protein is sTNFR-I, sTNFR-II, sTNFR fragments or sTNFR Fc.

13. The pharmaceutical composition of claim 9, wherein said TNF binding protein is present in an amount of up to about 20 mg.

20 14. The pharmaceutical composition of claim 10, wherein said methotrexate is present in an amount of up to about 25 mg.

25 15. A use of an anti-inflammatory drug, other than a non-TNF binding protein, in the preparation of a medicament for treating an acute or chronic inflammatory disease in a mammal in combination with the administration of a TNF binding protein.

30 16. The use of Claim 15, wherein the anti-inflammatory drug is methotrexate.

35 17. The use according to claim 16 wherein the methotrexate in the medicament is up to about 25 mg.

FOI 2000-03220660

5 19. The use according to claims 15 through 17
 wherein said methotrexate is administered orally.

10

15

20

24. The use of according to Claim 21, wherein
25 the anti-inflammatory drug is a fas fusion protein.

30

add β^2